Frontlight ResearchEarly access
Active, not recruitingNo phase
Thoraflex Hybrid Post-Market Study
Key facts
- Who runs it
- Vascutek Ltd.
- Where
- Canada, Germany, Italy, and Netherlands7 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 182 people enrolled
- Started
- 25 May 2018
- Ended
- Jul 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- EQ-5D-5L QOL questionnaire
- Record updated
- 9 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Patient is aged 18 years or over on date of consent
- Patient is willing and able to comply with all study procedures and study visits
- Patient or their legally authorised representative (LAR) has given written informed consent to participate in study. For emergency patients only, retrospective consent is permissible
- Patient satisfies the inclusion criteria for one of the following categories:; A - Patient has acute thoracic aortic syndrome or B - Patient has subacute/ chronic dissection of the aorta or C - Patient has an aortic aneurysm (including connective tissue disorders)
- Patients with acute thoracic aortic syndrome:; Patient has acute thoracic aortic syndrome and requires repair or replacement of damaged or diseased vessels of the aortic arch (with or without involvement of the ascending aorta), and the descending aorta requires replacement, or, in the opinion of the investigator, the patient would derive clinical benefit from prophylactic treatment of the descending aorta. This includes patients with acute dissections, rupture of the aorta or PAU
- Patients with subacute/chronic dissection of the aorta:
- Patient requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta due to subacute/chronic dissection; And patient satisfies one or more of the following criteria:
- Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥5.5cm (including if asymptomatic) or
- Patient has aorta diameter <5.5cm and growth rate ≥0.5cm/year (including if asymptomatic) or
- Patient has ascending aorta diameter ≥4.5cm and requires valve repair or replacement
- Patients with an aortic aneurysm (including connective tissue disorders):
- Patient requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta; And patient satisfies one or more of the following criteria:
- Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥5.5cm (including if asymptomatic) or
- Patient has aorta diameter <5.5cm and growth rate ≥0.5cm/year (including if asymptomatic) or
- Patient has ascending aorta diameter ≥4.5cm and requires valve repair or replacement; or
- Patient has Marfan syndrome or other genetically mediated disorders with aortic sinus, or ascending aorta, or arch diameter ≥4.5cm, or, the ratio of the maximal ascending or aortic root area (Π r2) in cm2 divided by the patient's height in meters exceeds 10
Who cannot take part
- Patient is unfit for open surgical repair involving circulatory arrest
- Patient is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study, which in the opinion of the Investigator will impact on this study
- Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated
- Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure
- Patient has active endocarditis or an active infective disorder of the aorta
- Patient has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure
- Patient has an uncorrectable bleeding anomaly
- Patient has renal failure (defined as dialysis dependent)
- Patient has known sensitivity to polyester, nitinol or materials of bovine origin
- Patient has a co-morbidity causing expected survival to be less than 1 year
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a global, prospective non-interventional, multi-centre, post-market study of the Vascutek Thoraflex™ Hybrid system in patients with acute thoracic aortic syndrome, subacute/chronic dissection of the aorta and aortic aneurysm.
The 3 groups in the trial
- Acute thoracic aortic syndrome
60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
Treatment: EQ-5D-5L QOL questionnaire
- Subacute/chronic dissection of the aorta
60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
Treatment: EQ-5D-5L QOL questionnaire
- Aortic aneurysm
60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
Treatment: EQ-5D-5L QOL questionnaire
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 9 July 2025